Skip to main content

Loading market data...

PTGX

Protagonist Therapeutics, Inc.

NASDAQ • United states

$138.08

+$0.09

(+0.07%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Management
Credibility
Score

Protagonist Therapeutics, Inc. (PTGX)

Unavailable

Quotes may be delayed

$8.93B

Market Cap

989,917

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Protagonist Therapeutics, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

13 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Protagonist Therapeutics, Inc..

7 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Protagonist Therapeutics, Inc..

5 Aug 2026

Protagonist Therapeutics, Inc. securities registration filing

Protagonist Therapeutics, Inc. filed a registration or prospectus document concerning securities.

5 Aug 2026

Protagonist Therapeutics, Inc. filed Form 10-Q

Protagonist Therapeutics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

Protagonist Therapeutics, Inc. reported Operating or financial results

Protagonist Therapeutics, Inc. filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$420.08M

Total assets (USD)$885.54M

Total liabilities (USD)$44.00M

Shareholders' equity (USD)$841.54M

Long-term debt (USD)$9.83M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$213.48M	$158.77M	$162.85M	$2.29	10-Q · 5 Aug 2026
Q2 2025	$5.55M	−$42.04M	−$34.77M	−$0.55	10-Q · 5 Aug 2026
Q3 2017	$8.78M	−$4.98M	−$4.83M	−$0.29	10-Q · 7 Nov 2017
Q3 2016	$0	−$7.14M	−$7.08M	−$0.87	10-Q · 7 Nov 2017

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $174.58

26.4% upside potential

📈

Strong Buy

Unavailable

👍

Buy

13

⏸️

Hold

0

📉

Sell

0

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 22 Oct 2026, 06:49 UTC Targets range 149.00–190.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

30

Sep 2026

Ali Asif

Chief Financial Officer

Option exercise

$23.72 per share

58,629 shares

30

Sep 2026

Ali Asif

Chief Financial Officer

Open-market sale

$141.78 per share

58,629 shares

10

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Option exercise

$21.58 per share

7,278 shares

10

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Open-market sale

$144.10 per share

7,278 shares

9

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Option exercise

$21.58 per share

63,548 shares

9

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Open-market sale

$146.18 per share

63,548 shares

8

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Option exercise

$21.58 per share

54,174 shares

8

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Open-market sale

$145.87 per share

54,174 shares

3

Sep 2026

PATEL DINESH V PH D

Director, President and CEO

Gift

Unavailable per share

510 shares

11

Aug 2026

PATEL DINESH V PH D

Director, President and CEO

Option exercise

$21.58 per share

34,239 shares

Top Shareholders

Blackrock, Inc.

10,307,837 shares

5.404% change

6/30/2026

Farallon Capital Management, L.L.C.

6,348,906 shares

0% change

6/30/2026

Vanguard Group Inc

5,413,690 shares

27.165% change

12/31/2025

Rtw Investments, Lp

5,061,175 shares

0.042% change

6/30/2026

Vanguard Portfolio Management Llc

3,629,298 shares

4.254% change

6/30/2026

Wellington Management Group Llp

3,416,781 shares

-5.08% change

6/30/2026

Ubs Group Ag

3,399,221 shares

-34.35% change

6/30/2026

State Street Corp

3,321,554 shares

6.571% change

6/30/2026

Janus Henderson Group Ltd.

2,891,527 shares

9.115% change

3/31/2026

Vanguard Capital Management Llc

2,853,394 shares

1.693% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 22 Oct 2026, 06:49 UTC· 2 hours ago

Research coverage and investment tools

Protagonist Therapeutics, Inc. (PTGX) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$138.08 on 21 Oct 2026. That is 74% of the way from its 52-week low of US$73.08 to its 52-week high of US$160.81. Its market capitalisation was US$8.93 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$213.48M	$158.77M	$162.85M	$2.29	—	74.4%	$218.88M	10-Q · 5 Aug 2026 (opens in a new tab)
Q2 2025	$5.55M	−$42.04M	−$34.77M	−$0.55	—	-758.0%	−$29.59M	10-Q · 5 Aug 2026 (opens in a new tab)
Q3 2017	$8.78M	−$4.98M	−$4.83M	−$0.29	—	-56.7%	$40.51M	10-Q · 7 Nov 2017 (opens in a new tab)
Q3 2016	$0	−$7.14M	−$7.08M	−$0.87	—	—	—	10-Q · 7 Nov 2017 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/5/2026	$2.29	$2.11	+8.5%
Mar 2026	5/5/2026	$0.05	−$0.65	+107.7%
Dec 2025	2/25/2026	−$0.69	−$0.53	-30.2%
Sep 2025	11/6/2025	−$0.62	−$0.59	-5.1%

Cash and equivalents: $420.08M
Total assets: $885.54M
Total liabilities: $44.00M
Shareholders' equity: $841.54M
Long-term debt: $9.83M

SCHEDULE 13G/A · 13 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Protagonist Therapeutics, Inc..
SCHEDULE 13G · 7 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Protagonist Therapeutics, Inc..
S-8 · 5 Aug 2026

Protagonist Therapeutics, Inc. securities registration filing (opens in a new tab)

Protagonist Therapeutics, Inc. filed a registration or prospectus document concerning securities.
10-Q · 5 Aug 2026

Protagonist Therapeutics, Inc. filed Form 10-Q (opens in a new tab)

Protagonist Therapeutics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

Protagonist Therapeutics, Inc. reported Operating or financial results (opens in a new tab)

Protagonist Therapeutics, Inc. filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Ali Asif Chief Financial Officer	30 Sep 2026	Option exercise (M)	+58,629	$23.72	Form 4 (opens in a new tab)
Ali Asif Chief Financial Officer	30 Sep 2026	Open-market sale (S)	−58,629	$141.78	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	10 Sep 2026	Option exercise (M)	+7,278	$21.58	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	10 Sep 2026	Open-market sale (S)	−7,278	$144.10	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	9 Sep 2026	Option exercise (M)	+63,548	$21.58	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	9 Sep 2026	Open-market sale (S)	−63,548	$146.18	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	8 Sep 2026	Option exercise (M)	+54,174	$21.58	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	8 Sep 2026	Open-market sale (S)	−54,174	$145.87	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	3 Sep 2026	Gift (G)	−510	—	Form 4 (opens in a new tab)
PATEL DINESH V PH D Director, President and CEO	11 Aug 2026	Option exercise (M)	+34,239	$21.58	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	10,307,837	5.404%
Farallon Capital Management, L.L.C.	6/30/2026	6,348,906	0%
Vanguard Group Inc	12/31/2025	5,413,690	27.165%
Rtw Investments, Lp	6/30/2026	5,061,175	0.042%
Vanguard Portfolio Management Llc	6/30/2026	3,629,298	4.254%
Wellington Management Group Llp	6/30/2026	3,416,781	-5.08%
Ubs Group Ag	6/30/2026	3,399,221	-34.35%
State Street Corp	6/30/2026	3,321,554	6.571%
Janus Henderson Group Ltd.	3/31/2026	2,891,527	9.115%
Vanguard Capital Management Llc	6/30/2026	2,853,394	1.693%

Previous close: 137.99 USD
Day range: 138.03 – 141.85 USD
52-week range: 73.08 – 160.81 USD
Volume: 989,917
Market cap: $8.93B
Average volume: 662,616
EPS (diluted, trailing four quarters to 30 Jun 2026): 1.03 USD
Shares outstanding: 64.71M
Beta (5Y monthly): 1.22

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 13 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:08 UTC· 1 hour ago

EPS: SEC EDGAR filings (opens in a new tab) Checked 20 Oct 2026, 11:13 UTC· 1 day ago 10-Q filed 5 Aug 2026

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for PTGX yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.